Tharimmune Net Income Over Time
| THAR Stock | 3.93 0.80 16.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tharimmune Performance and Tharimmune Correlation. Tharimmune | Build AI portfolio with Tharimmune Stock |
Can Biotechnology industry sustain growth momentum? Does Tharimmune have expansion opportunities? Factors like these will boost the valuation of Tharimmune. If investors know Tharimmune will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Tharimmune demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Tharimmune is measured differently than its book value, which is the value of Tharimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Tharimmune's value that differs from its market value or its book value, called intrinsic value, which is Tharimmune's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Tharimmune's market value can be influenced by many factors that don't directly affect Tharimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tharimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tharimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Tharimmune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Tharimmune and related stocks such as BioLineRx, GeoVax Labs, and Adlai Nortye Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| ANL | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (63.4 M) | (56.7 M) | (58.8 M) | (104.9 M) | (51.9 M) | (46.7 M) | (49 M) |
| LNAI | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (113.4 M) | (39.7 M) | (88.4 M) | (178 M) | (160.2 M) | (152.2 M) |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| APLM | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (74.8 M) | (94.8 M) | (240.8 M) | (172.6 M) | (53.9 M) | (48.5 M) | (50.9 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (34.4 M) | (31 M) | (32.6 M) |
| MBRX | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (3.9 M) | (9.8 M) | (11.9 M) | (13.2 M) | (17.4 M) | (15.9 M) | (29 M) | (29.8 M) | (21.8 M) | (19.6 M) | (20.6 M) |
Tharimmune and related stocks such as BioLineRx, GeoVax Labs, and Adlai Nortye Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Tharimmune financial statement analysis. It represents the amount of money remaining after all of Tharimmune operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Tharimmune | THAR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 34 Shrewsbury Avenue, |
| Exchange | NASDAQ Exchange |
null 3.93
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.